Document is current

Article History

Received: 11 August 2025

Accepted: 18 September 2025

First Online: 8 October 2025

Declarations

:

: Bruce Strober: Consultant (honoraria) for AbbVie, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Eli Lilly, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Novartis, Oruka, Pfizer, Protagonist, Rapt, Regeneron, Sanofi-Genzyme, Takeda, UCB, and Union Therapeutics; stock options from Connect Biopharma and Mindera Health; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, Janssen, Regeneron, and Sanofi-Genzyme; Scientific Co-Director (consulting fee): CorEvitas Psoriasis Registry; investigator for CorEvitas Psoriasis Registry; editor-in-chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis. Wolf-Henning Boehncke: Received honoraria as a speaker and/or advisor from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB. James G. Krueger: Grants paid to institution from AbbVie, Amgen, Akros, Allergan, Avillion, Biogen MA, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, Eli Lilly, Exicure, Incyte, Innovaderm, Janssen, LEO Pharma, Novan, Novartis, Parexel, Pfizer, Regeneron, Sienna, UCB, and Vitae; Personal fees from AbbVie, Aclaris, Allergan, Almirall, Amgen, Arena, Aristea, Asana, Aurigne, BiogenIdec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Escalier, Galapagos, LEO Pharma, Menlo, Nimbus, Novartis, Pfizer, Sanofi, Sienna, Sun Pharma, UCB, Valeant, and Ventyx. Nina Magnolo: Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dr. Wolff, Eli Lilly, Janssen, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Sanofi and UCB. Ronald Vender: Grants/research support from AbbVie, Amgen, Centocor, Dermavant, Dermira, Eli Lilly, Galderma, GSK, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Takeda, and UCB; speakers bureau/honoraria from AbbVie, Actelion, Amgen, Bausch Health, Celgene, Cipher, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, Merck, Novartis, Pfizer, and UCB; consulting fees from AbbVie, Actelion, Amgen, Bausch Health, Celgene, Cipher, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, Merck, Novartis, Palladin, Pfizer, and UCB. Richard B. Warren: Consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE Therapeutics, Eli Lilly, GSK, Janssen, LEO Pharma, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma, UCB, and Union; research grants to his institution from AbbVie, Almirall, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB; honoraria from AbbVie, Almirall, Bristol Myers Squibb, Eli Lilly, Galderma, Janssen, and Novartis. José Manuel López Pinto, Bengt Hoepken: Employee and shareholder of UCB. Sarah Kavanagh: Consultant for Aclipse Therapeutics, Aliada Therapeutics, Allay Therapeutics, Autobahn Therapeutics, Cognition Therapeutics, Colorado Prevention Center, Karuna Therapeutics, Kisbee Therapeutics, LB Pharmaceuticals, Nesos, Novartis, Onward Medical, PharPoint Research, Summit Analytical, Therini Bio, Tonix Pharmaceuticals, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials, and Zosano Pharma. Paolo Gisondi: Consultant for AbbVie, Abiogen, Almirall, Celgene, Eli Lilly, Janssen, LEO Pharma, Merck, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Sanofi, UCB.

: Study protocols, amendments, and patient informed consent were reviewed by a national, regional, or independent ethics committee or institutional review board. All studies were conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonization Good Clinical Practice requirements, the principles of the Declaration of Helsinki, and the local laws of the countries involved. All participants provided informed written consent documented in accordance with local regulations.